TX16 (bevacizumab biosimilar) / Tanvex BioPharma - LARVOL DELTA

Taifu-KY completed the capital increase before the end of KY. The company obtained the key process patent of the two drugs [Google translation] (money.udn.com) - "...obtained key process patents for its two self-developed drugs TX05 and TX16, and the chances of success in subsequent challenges to the original patents have greatly increased....Taifu's TX05 Phase III human clinical trial has been completed on October 21st, US time. It is expected to eliminate blindness in the first quarter of next year and submit a drug certification application to the US Food and Drug Administration (FDA) in the middle of next year. It will be launched in 2022; TX16 is going to undergo Phase III clinical testing. The legal person estimates that Taifu's TX-01 and TX-05 are expected to start sales in the third quarter of next year. The two drugs are expected to contribute more than 10 million US dollars in revenue."

Biosimilar launch • BLA • Patent • Sales • Trial status • Oncology

Assessment of Fraction Exhaled Nitric Oxide in Patients Undergoing Hyperbaric Oxygen Therapy (ATS 2020) - "When looking at those who are at ATA of 2.5, significance was seen only in baseline measurement 20 (median Pre Tx 16 (6,24), post-Tx 8.5 (5,11), p=0.01). Results in this ongoing study shows that HBOT causes no significant changes in FeNO levels in patients undergoing HBOT. More research with a higher sample is needed to fully understand FeNo levels, specifically in each HBOT indication."

Clinical